GlassScriptPhysician profile
Sarah E Metzger
NPI 1255642971
$613.19
in general payments reported to CMS, 2019-2025
11 companies · $71.74 in 2025
The $71.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $78.96 · 2022: $23.04 · 2023: $71.30 · 2024: $90.69 · 2025: $71.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $244.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.72 | 2019-2020 | |
| Novo Nordisk INC | $52.58 | 2019 | |
| Merck Sharp & Dohme LLC | $47.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $36.79 | 2019 | |
| Pfizer INC. | $36.10 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $25.15 | 2019 | |
| Covidien LP | $14.99 | 2020 | |
| Ethicon US, LLC | $14.86 | 2019 | |
| Lilly USA, LLC | $11.89 | 2020 | |
| Amarin Pharma, INC. | $11.43 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Metzger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.